New York, July 07, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Genitourinary Drugs Industry" - https://www.reportlinker.com/p06044618/?utm_source=GNW
Urologicals, one of the segments analyzed in the report, is projected to record a 3.2% CAGR and reach US$10.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Anti-Infectives segment is readjusted to a revised 1.6% CAGR for the next 8-year period.
The U.S. Market is Estimated at $9.3 Billion, While China is Forecast to Grow at 4.2% CAGR
The Genitourinary Drugs market in the U.S. is estimated at US$9.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.9 Billion by the year 2030 trailing a CAGR of 4.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.3% and 2.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5.1 Billion by the year 2030.
Select Competitors (Total 42 Featured)
- Astellas Pharma, Inc.
- Bayer AG
- Daiichi Sankyo Co., Ltd.
- GlaxoSmithKline PLC
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer, Inc.
- Sanofi SA
- Shandong Luoxin Pharmaceutical Group Stock co., ltd.
- Yichang HEC Changjiang Pharmaceutical Company Limited
Read the full report: https://www.reportlinker.com/p06044618/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Genitourinary Drugs - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Genitourinary Drugs Market Analysis of Annual
Sales in US$ Million for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for
Genitourinary Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 3: World Historic Review for Genitourinary Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 4: World 16-Year Perspective for Genitourinary Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030
Table 5: World Recent Past, Current & Future Analysis for
Urologicals by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 6: World Historic Review for Urologicals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 7: World 16-Year Perspective for Urologicals by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 8: World Recent Past, Current & Future Analysis for
Anti-Infectives by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 9: World Historic Review for Anti-Infectives by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 10: World 16-Year Perspective for Anti-Infectives by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 11: World Recent Past, Current & Future Analysis for
Gynecological by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 12: World Historic Review for Gynecological by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 13: World 16-Year Perspective for Gynecological by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 14: World Recent Past, Current & Future Analysis for
Hormonal Therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 15: World Historic Review for Hormonal Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 16: World 16-Year Perspective for Hormonal Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 17: World Recent Past, Current & Future Analysis for
Other Types by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 18: World Historic Review for Other Types by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 19: World 16-Year Perspective for Other Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 20: World Recent Past, Current & Future Analysis for
Prostate Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 21: World Historic Review for Prostate Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 22: World 16-Year Perspective for Prostate Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 23: World Recent Past, Current & Future Analysis for
Renal Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 24: World Historic Review for Renal Cancer by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 25: World 16-Year Perspective for Renal Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 26: World Recent Past, Current & Future Analysis for
Sexually Transmitted Diseases by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 27: World Historic Review for Sexually Transmitted
Diseases by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 28: World 16-Year Perspective for Sexually Transmitted
Diseases by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030
Table 29: World Recent Past, Current & Future Analysis for
Cervical Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 30: World Historic Review for Cervical Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 31: World 16-Year Perspective for Cervical Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 32: World Recent Past, Current & Future Analysis for
Ovarian Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 33: World Historic Review for Ovarian Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 34: World 16-Year Perspective for Ovarian Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 35: World Recent Past, Current & Future Analysis for
Erectile Dysfunction by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 36: World Historic Review for Erectile Dysfunction by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 37: World 16-Year Perspective for Erectile Dysfunction by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 38: World Recent Past, Current & Future Analysis for
Bladder Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 39: World Historic Review for Bladder Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 40: World 16-Year Perspective for Bladder Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 41: World Recent Past, Current & Future Analysis for
Urinary Tract Infection by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 42: World Historic Review for Urinary Tract Infection by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 43: World 16-Year Perspective for Urinary Tract Infection
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 44: World Recent Past, Current & Future Analysis for
Other Indications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 45: World Historic Review for Other Indications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 46: World 16-Year Perspective for Other Indications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 47: USA Recent Past, Current & Future Analysis for
Genitourinary Drugs by Type - Urologicals, Anti-Infectives,
Gynecological, Hormonal Therapy and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 48: USA Historic Review for Genitourinary Drugs by Type -
Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy
and Other Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR
Table 49: USA 16-Year Perspective for Genitourinary Drugs by
Type - Percentage Breakdown of Value Sales for Urologicals,
Anti-Infectives, Gynecological, Hormonal Therapy and Other
Types for the Years 2014, 2023 & 2030
Table 50: USA Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Renal
Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian
Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract
Infection and Other Indications - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 51: USA Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Renal Cancer, Sexually
Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile
Dysfunction, Bladder Cancer, Urinary Tract Infection and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR
Table 52: USA 16-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical
Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer,
Urinary Tract Infection and Other Indications for the Years
2014, 2023 & 2030
CANADA
Table 53: Canada Recent Past, Current & Future Analysis for
Genitourinary Drugs by Type - Urologicals, Anti-Infectives,
Gynecological, Hormonal Therapy and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 54: Canada Historic Review for Genitourinary Drugs by
Type - Urologicals, Anti-Infectives, Gynecological, Hormonal
Therapy and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 55: Canada 16-Year Perspective for Genitourinary Drugs by
Type - Percentage Breakdown of Value Sales for Urologicals,
Anti-Infectives, Gynecological, Hormonal Therapy and Other
Types for the Years 2014, 2023 & 2030
Table 56: Canada Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Renal
Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian
Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract
Infection and Other Indications - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 57: Canada Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Renal Cancer, Sexually
Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile
Dysfunction, Bladder Cancer, Urinary Tract Infection and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR
Table 58: Canada 16-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical
Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer,
Urinary Tract Infection and Other Indications for the Years
2014, 2023 & 2030
JAPAN
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 59: Japan Recent Past, Current & Future Analysis for
Genitourinary Drugs by Type - Urologicals, Anti-Infectives,
Gynecological, Hormonal Therapy and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 60: Japan Historic Review for Genitourinary Drugs by Type -
Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy
and Other Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR
Table 61: Japan 16-Year Perspective for Genitourinary Drugs by
Type - Percentage Breakdown of Value Sales for Urologicals,
Anti-Infectives, Gynecological, Hormonal Therapy and Other
Types for the Years 2014, 2023 & 2030
Table 62: Japan Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Renal
Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian
Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract
Infection and Other Indications - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 63: Japan Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Renal Cancer, Sexually
Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile
Dysfunction, Bladder Cancer, Urinary Tract Infection and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR
Table 64: Japan 16-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical
Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer,
Urinary Tract Infection and Other Indications for the Years
2014, 2023 & 2030
CHINA
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 65: China Recent Past, Current & Future Analysis for
Genitourinary Drugs by Type - Urologicals, Anti-Infectives,
Gynecological, Hormonal Therapy and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 66: China Historic Review for Genitourinary Drugs by Type -
Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy
and Other Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR
Table 67: China 16-Year Perspective for Genitourinary Drugs by
Type - Percentage Breakdown of Value Sales for Urologicals,
Anti-Infectives, Gynecological, Hormonal Therapy and Other
Types for the Years 2014, 2023 & 2030
Table 68: China Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Renal
Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian
Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract
Infection and Other Indications - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 69: China Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Renal Cancer, Sexually
Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile
Dysfunction, Bladder Cancer, Urinary Tract Infection and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR
Table 70: China 16-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical
Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer,
Urinary Tract Infection and Other Indications for the Years
2014, 2023 & 2030
EUROPE
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 71: Europe Recent Past, Current & Future Analysis for
Genitourinary Drugs by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 72: Europe Historic Review for Genitourinary Drugs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 73: Europe 16-Year Perspective for Genitourinary Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030
Table 74: Europe Recent Past, Current & Future Analysis for
Genitourinary Drugs by Type - Urologicals, Anti-Infectives,
Gynecological, Hormonal Therapy and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 75: Europe Historic Review for Genitourinary Drugs by
Type - Urologicals, Anti-Infectives, Gynecological, Hormonal
Therapy and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 76: Europe 16-Year Perspective for Genitourinary Drugs by
Type - Percentage Breakdown of Value Sales for Urologicals,
Anti-Infectives, Gynecological, Hormonal Therapy and Other
Types for the Years 2014, 2023 & 2030
Table 77: Europe Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Renal
Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian
Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract
Infection and Other Indications - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 78: Europe Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Renal Cancer, Sexually
Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile
Dysfunction, Bladder Cancer, Urinary Tract Infection and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR
Table 79: Europe 16-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical
Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer,
Urinary Tract Infection and Other Indications for the Years
2014, 2023 & 2030
FRANCE
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 80: France Recent Past, Current & Future Analysis for
Genitourinary Drugs by Type - Urologicals, Anti-Infectives,
Gynecological, Hormonal Therapy and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 81: France Historic Review for Genitourinary Drugs by
Type - Urologicals, Anti-Infectives, Gynecological, Hormonal
Therapy and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 82: France 16-Year Perspective for Genitourinary Drugs by
Type - Percentage Breakdown of Value Sales for Urologicals,
Anti-Infectives, Gynecological, Hormonal Therapy and Other
Types for the Years 2014, 2023 & 2030
Table 83: France Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Renal
Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian
Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract
Infection and Other Indications - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 84: France Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Renal Cancer, Sexually
Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile
Dysfunction, Bladder Cancer, Urinary Tract Infection and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR
Table 85: France 16-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical
Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer,
Urinary Tract Infection and Other Indications for the Years
2014, 2023 & 2030
GERMANY
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 86: Germany Recent Past, Current & Future Analysis for
Genitourinary Drugs by Type - Urologicals, Anti-Infectives,
Gynecological, Hormonal Therapy and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 87: Germany Historic Review for Genitourinary Drugs by
Type - Urologicals, Anti-Infectives, Gynecological, Hormonal
Therapy and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 88: Germany 16-Year Perspective for Genitourinary Drugs
by Type - Percentage Breakdown of Value Sales for Urologicals,
Anti-Infectives, Gynecological, Hormonal Therapy and Other
Types for the Years 2014, 2023 & 2030
Table 89: Germany Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Renal
Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian
Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract
Infection and Other Indications - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 90: Germany Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Renal Cancer, Sexually
Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile
Dysfunction, Bladder Cancer, Urinary Tract Infection and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR
Table 91: Germany 16-Year Perspective for Genitourinary Drugs
by Indication - Percentage Breakdown of Value Sales for
Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases,
Cervical Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder
Cancer, Urinary Tract Infection and Other Indications for the
Years 2014, 2023 & 2030
ITALY
Table 92: Italy Recent Past, Current & Future Analysis for
Genitourinary Drugs by Type - Urologicals, Anti-Infectives,
Gynecological, Hormonal Therapy and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 93: Italy Historic Review for Genitourinary Drugs by Type -
Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy
and Other Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR
Table 94: Italy 16-Year Perspective for Genitourinary Drugs by
Type - Percentage Breakdown of Value Sales for Urologicals,
Anti-Infectives, Gynecological, Hormonal Therapy and Other
Types for the Years 2014, 2023 & 2030
Table 95: Italy Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Renal
Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian
Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract
Infection and Other Indications - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 96: Italy Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Renal Cancer, Sexually
Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile
Dysfunction, Bladder Cancer, Urinary Tract Infection and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR
Table 97: Italy 16-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical
Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer,
Urinary Tract Infection and Other Indications for the Years
2014, 2023 & 2030
UNITED KINGDOM
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 98: UK Recent Past, Current & Future Analysis for
Genitourinary Drugs by Type - Urologicals, Anti-Infectives,
Gynecological, Hormonal Therapy and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 99: UK Historic Review for Genitourinary Drugs by Type -
Urologicals, Anti-Infectives, Gynecological, Hormonal Therapy
and Other Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR
Table 100: UK 16-Year Perspective for Genitourinary Drugs by
Type - Percentage Breakdown of Value Sales for Urologicals,
Anti-Infectives, Gynecological, Hormonal Therapy and Other
Types for the Years 2014, 2023 & 2030
Table 101: UK Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Renal
Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian
Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract
Infection and Other Indications - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 102: UK Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Renal Cancer, Sexually
Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile
Dysfunction, Bladder Cancer, Urinary Tract Infection and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR
Table 103: UK 16-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Renal Cancer, Sexually Transmitted Diseases, Cervical
Cancer, Ovarian Cancer, Erectile Dysfunction, Bladder Cancer,
Urinary Tract Infection and Other Indications for the Years
2014, 2023 & 2030
SPAIN
Table 104: Spain Recent Past, Current & Future Analysis for
Genitourinary Drugs by Type - Urologicals, Anti-Infectives,
Gynecological, Hormonal Therapy and Other Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 105: Spain Historic Review for Genitourinary Drugs by
Type - Urologicals, Anti-Infectives, Gynecological, Hormonal
Therapy and Other Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 106: Spain 16-Year Perspective for Genitourinary Drugs by
Type - Percentage Breakdown of Value Sales for Urologicals,
Anti-Infectives, Gynecological, Hormonal Therapy and Other
Types for the Years 2014, 2023 & 2030
Table 107: Spain Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Renal
Cancer, Sexually Transmitted Diseases, Cervical Cancer, Ovarian
Cancer, Erectile Dysfunction, Bladder Cancer, Urinary Tract
Infection and Other Indications - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 108: Spain Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Renal Cancer, Sexually
Transmitted Diseases, Cervical Cancer, Ovarian Cancer, Erectile
Dysfunction, Bladder Cancer, Urinary Tract Infection and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR
Table 109: Spain 16-Year Perspective for Genitourinary Drugs by
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06044618/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
